Evidence map›Paper›PMID 36320392›Full record

ArticleChemical science2022

Dual reactivity disulfide bridging reagents; enabling new approaches to antibody fragment bioconjugation.

Alina Chrzastek, Ioanna A Thanasi, James A Irving, Vijay Chudasama, James R Baker

Abstract read
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alina ChrzastekDepartment of Chemistry, University College London 20 Gordon Street WC1H OAJ London UK j.r.baker@ucl.ac.uk v.chudasama@ucl.ac.uk.ORCID https://orcid.org/0000-0003-1419-0311
Ioanna A ThanasiDepartment of Chemistry, University College London 20 Gordon Street WC1H OAJ London UK j.r.baker@ucl.ac.uk v.chudasama@ucl.ac.uk.
James A IrvingUCL Respiratory, Rayne Institute, University College London WC1E 6JF London UK.ORCID https://orcid.org/0000-0003-3204-6356
Vijay ChudasamaDepartment of Chemistry, University College London 20 Gordon Street WC1H OAJ London UK j.r.baker@ucl.ac.uk v.chudasama@ucl.ac.uk.ORCID https://orcid.org/0000-0002-8876-3285
James R BakerDepartment of Chemistry, University College London 20 Gordon Street WC1H OAJ London UK j.r.baker@ucl.ac.uk v.chudasama@ucl.ac.uk.ORCID https://orcid.org/0000-0002-7223-2279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disulfide bridging, also known as disulfide stapling, is a powerful strategy for the construction of site-selective protein bioconjugates. Here we describe the first examples of a new class of such reagents, containing a 'stable-labile' design. These dual-reactive reagents are designed to form a stable bond to one cysteine and a labile bond to the second; resulting in a robust attachment to the protein with one end of the bridge, whilst the other end serves as a reactive handle for subsequent bioconjugation. By incorporating thioesters into these bridges, we demonstrate that they are primed for native chemical ligation (NCL) with N-terminal cysteines; offering an alternative to the requirement for C-terminal thioesters for use in such ligations. Alternatively, the use of hydrazine as the ligating nucleophile enables a separate cargo to be attached to each cysteine residue, which are exploited to insert variably cleavable linkers. These methodologies are demonstrated on an antibody fragment, and serve to expand the scope of disulfide bridging strategies whilst offering a convenient route to the construction of multifunctional antibody fragment conjugates.

Identifiers

PMID36320392
PMCPMC9555722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.